Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine

Phase 4 Terminated 29 enrolled Amgen Novartis · collab

RandomizedParallel-groupQuadruple-blindPrevention

Summary

To evaluate the effect of erenumab compared to placebo on disability in employed subjects with episodic migraine (EM) who have previously failed 1 or more migraine preventive treatments.

Timeline

Start: 2019-12-04
Primary completion: 2021-07-28
Completion: 2021-07-28

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Erenumab	Monoclonal antibody	—	Subcutaneous

Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine

Summary

Timeline

Drugs

Indications